Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 1, 2003, Pages 135-139

  Paolucci, Stefania ^a   Baldanti, Fausto ^a   Zavattoni, Maurizio ^a   Comolli, Giuditta ^a   Labò, Nazzarena ^a   Menzo, Stefano ^b   Clementi, Massimo ^c   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ACCURACY; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; PHENOTYPE; PROTEIN EXPRESSION; VIRUS ISOLATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HELA CELLS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHENOTYPE; RECOMBINATION, GENETIC;

EID: 0037259499     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg016     Document Type: Article

References (10)

1. Perrin, L. & Telenti, A. (1998). HIV treatment failure: testing for HIV resistance in clinical practice. Science 280, 1871-3.
2. Haubrich, R. & Demeter, L. (2001). Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. Journal of Acquired Immune Deficiency Syndromes 26, S51-9.
3. Demeter, L. & Haubrich, R. (2001). Phenotypic and genotypic resistance assays: methodology, reliability and interpretations. Journal of Acquired Immune Deficiency Syndromes 26, S3-9
4. Hertogs, K., Bloor, S., Kemp, S. D., Van den Eynde, C., Alcorn, T. M., Pauwels, R. et al. (2000). Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14, 1203-10.
5. Paolucci, S., Baldanti, F., Maserati, M., Castelli, F., Suter, F., Maggiolo, F. et al. (2000). Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. Antiviral Research 45, 101-14.
6. Paolucci, S., Baldanti, F., Campanini, G., Zavattoni, M., Cattaneo, E., Dossena L. et al. (2001). Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. Journal of Medical Virology 65, 207-17.
7. The AIDS Clinical Trials Group Virology Technical Advisory Committee and the Division of AIDS, National Institutes of Allergy and Infectious Diseases. (1994). HIV Drug Susceptibility Assay. ACTG Virology Manual for HIV Laboratories. RES 1-12. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA.
8. Cattaneo, E., Zavattoni, M., Baldanti, F, Sarasini, A., Caselli, D., Maccabruni, A. et al. (1999). Diagnostic value of viral culture, polymerase chain reaction and western blot for HIV-1 infection in 218 infants born to HIV-infected mothers and examined at different ages. New Microbiologica 22, 281-91.
9. Menzo, S., Rusconi, S., Monachetti, A., Colombo, M. C., Violin, M., Bagnarelli, P. et al. (2000). Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. AIDS 14, 1101-10.
10. Kantor, R., Machekano, R., Gonzales, M. J., Dupnik, K., Schapiro, J. M. & Shafer, R. W. (2001). Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Research 29, 296-9.